智通财经APP讯，海普瑞(002399.SZ)发布2024年年度报告，报告期内，公司实现营业收入52.81亿元，同比下降3.03%。实现归属于上市公司股东的净利润6.47亿元。实现归属于上市公司股东的扣除非经常性损益的净利润2.54亿元。基本每股收益为0.4408元。拟向全体股东每10股派发现金红利2.50元(含税)。
报告期内，本集团肝素产业链业务实现销售收入人民币40.55亿元，同比下降5.40%。其中制剂销量实现两位数增长，年度销量取得新高，实现销售收入人民币29.86亿元，同比上涨0.24%，占本集团总收入56.55%，毛利率为33.60%，同比下降了9.97个百分点。由于集采中标因素，本集团在中国市场的产品销量显著增加，但集采价格较2023年上半年同期销售价格下调幅度较大，使得制剂业务在报告期内整体毛利及毛利率受到较大影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.